as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹640.6
Change
-9.9 (-1.52%)
Open
₹651.3
Prev. Close
₹650.5
Day High
₹651.3
Day Low
₹638.5
Volume Analysis
Traded
71,375
Delivered
38,558
Delivery %
54.02%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (1)
- •Promoter holding is rising
Weaknesses (2)
- •Low return on equity (-0.13%)
- •Below-average fundamentals quality score (49/100)
Opportunities (0)
No signal for this stock
Threats (1)
- •FII holding has been falling
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹661.24 | ₹656.27 | ₹648.44 | ₹643.47 | ₹635.64 | ₹630.67 | ₹622.84 |
| Fibonacci | ₹656.27 | ₹651.38 | ₹648.36 | ₹643.47 | ₹638.58 | ₹635.56 | ₹630.67 |
| Camarilla | ₹644.12 | ₹642.95 | ₹641.77 | ₹643.47 | ₹639.43 | ₹638.25 | ₹637.08 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+13.76%
1 Week
-5.27%
1 Month
-1.18%
3 Months
+3.84%
6 Months
+16.88%
1 Year
+13.77%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
DuPont ROE Breakdown
2.31%
Net margin 2.41% × asset turnover 0.56x × equity multiplier 1.71x
Company Overview
Sector
Healthcare
Market Cap
₹3,347 Cr
P/E (TTM)
70.7
ROE
-0.13%
Book Value
₹296.0
Face Value
₹10.0
Source: Screener.in (Consolidated figures) — data as of 15 Nov 2026. Not investment advice.
TopFund Analysis
Solara Active Pha Sci Ltd scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 49/100. The strongest factor is Financial Strength (94/100), while Growth (0/100) is the weakest area to weigh before deciding. Notably: Promoter holding is rising; low return on equity (-0.13%); below-average fundamentals quality score (49/100). FII holding has been falling.
TopFund Score — Fundamentals Quality
49/100 — WeakData confidence: 77/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company has reduced debt.
- −Company has low interest coverage ratio.
- −The company has delivered a poor sales growth of -3.27% over past five years.
- −Company has a low return on equity of -12.0% over last 3 years.
- −Promoters have pledged 52.0% of their holding.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Transcript of Earnings Conference call pertaining to financial results of the Company for the quarter ended September 30, 2026
Solara Active Pharma Sciences Limited has informed regarding the copy of Newspaper publication informing about Final Reminder-cum-Forfeiture Notice for the payment of First ....
Final reminder for partly paid rights shares: pay ₹131.25 and ₹112.50 by Nov 5, 2026.
Solara Active Pharma Sciences Limited has informed regarding the copy of the Newspaper publication providing extract of the unaudited Financial Results (Standalone and Consolidated) ....
Crisil report for Q2 FY27 rights issue use shows no deviation; Rs 7.07 crore unutilized.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 425 | 212 | 299 | 363 | 347 | 300 | 273 | 319 | 314 | 349 | 387 | 382 | 417 |
| Expenses + | 388 | 374 | 290 | 322 | 286 | 243 | 228 | 262 | 279 | 312 | 330 | 320 | 340 |
| Operating Profit | 38 | -162 | 10 | 42 | 61 | 58 | 45 | 57 | 35 | 37 | 58 | 62 | 77 |
| OPM % | 9.0% | -76.0% | 3.3% | 12.0% | 18.0% | 19.0% | 17.0% | 18.0% | 11.0% | 11.0% | 15.0% | 16.0% | 18.0% |
| Other Income + | -4 | -62 | -120 | 1 | 0 | 1 | 6 | 1 | 0 | -7 | 6 | 3 | -4 |
| Interest | 24 | 25 | 31 | 31 | 28 | 27 | 29 | 24 | 21 | 22 | 28 | 22 | 18 |
| Depreciation | 26 | 26 | 25 | 25 | 25 | 25 | 24 | 24 | 24 | 26 | 26 | 27 | 27 |
| Profit before tax | -17 | -275 | -167 | -13 | 8 | 8 | -2 | 11 | -10 | -17 | 10 | 16 | 28 |
| Tax % | 0.0% | 0.0% | 53.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Profit + | -17 | -275 | -255 | -13 | 8 | 8 | -2 | 11 | -10 | -17 | 10 | 16 | 28 |
| EPS in Rs | -4 | -70 | -65 | -4 | 2 | 2 | -1 | 3 | -3 | -5 | 3 | 3 | 6 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| YoY Sales growth | 26 | -46 | -21 | 3 | -18 | 42 | -9 | -12 | -10 | 16 | 42 | 20 | 33 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 521 | 1,387 | 1,322 | 1,617 | 1,268 | 1,444 | 1,289 | 1,284 | 1,369 | 1,535 |
| Expenses + | 464 | 1,174 | 1,062 | 1,231 | 1,188 | 1,309 | 1,384 | 1,077 | 1,182 | 1,301 |
| Operating Profit | 57 | 213 | 260 | 386 | 81 | 134 | -95 | 206 | 187 | 234 |
| OPM % | 11.0% | 15.0% | 20.0% | 24.0% | 6.0% | 9.0% | -7.0% | 16.0% | 14.0% | 15.0% |
| Other Income + | 2 | 12 | 27 | 29 | 16 | 22 | -185 | 8 | 0 | -2 |
| Interest | 25 | 82 | 78 | 84 | 75 | 90 | 105 | 115 | 95 | 89 |
| Depreciation | 34 | 83 | 94 | 109 | 112 | 111 | 103 | 99 | 100 | 105 |
| Profit before tax | 0 | 60 | 115 | 222 | -91 | -45 | -488 | 1 | -7 | 37 |
| Tax % | -70.0% | 1.0% | 0.0% | 0.0% | -36.0% | -50.0% | 16.0% | 0.0% | 0.0% | — |
| Net Profit + | 0 | 59 | 115 | 221 | -58 | -22 | -567 | 1 | -7 | 37 |
| EPS in Rs | — | 21 | 39 | 57 | -15 | -6 | -145 | 0 | -2 | 7 |
| Dividend Payout % | 0.0% | 22.0% | 5.0% | 11.0% | 0.0% | -49.0% | 0.0% | 0.0% | 0.0% | — |
| Sales growth | — | 166 | -5 | 22 | -22 | 14 | -11 | 0 | 7 | 27 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 739 | 930 | 1,059 | 1,553 | 1,489 | 1,464 | 898 | 1,054 | 1,208 | 1,388 |
| Borrowings + | 633 | 538 | 722 | 621 | 1,037 | 1,013 | 1,012 | 796 | 687 | 591 |
| Other Liabilities + | 425 | 466 | 346 | 404 | 383 | 386 | 406 | 342 | 393 | 427 |
| Total Liabilities | 1,821 | 1,960 | 2,153 | 2,614 | 2,945 | 2,899 | 2,351 | 2,232 | 2,333 | 2,454 |
| Fixed Assets + | 1,086 | 1,218 | 1,397 | 1,382 | 1,356 | 1,364 | 1,268 | 1,193 | 1,238 | 1,201 |
| CWIP | 71 | 40 | 40 | 88 | 239 | 238 | 256 | 280 | 205 | 208 |
| Investments | 1 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 5 | 3 |
| Other Assets + | 663 | 701 | 716 | 1,144 | 1,350 | 1,295 | 825 | 757 | 886 | 1,043 |
| Total Assets | 1,821 | 1,960 | 2,153 | 2,614 | 2,945 | 2,899 | 2,351 | 2,232 | 2,333 | 2,454 |
| Equity Capital | 25 | 26 | 27 | 36 | 36 | 36 | 36 | 40 | 45 | 48 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 49 | 166 | 242 | 155 | -242 | 156 | 109 | 213 | 153 |
| Cash from Investing Activity + | -85 | -113 | -359 | -106 | -243 | -81 | -4 | -37 | -99 |
| Cash from Financing Activity + | 68 | -23 | 97 | 92 | 334 | -113 | -106 | -180 | -54 |
| Net Cash Flow | 31 | 30 | -20 | 142 | -151 | -38 | 0 | -4 | 1 |
| Free Cash Flow | 14 | 108 | -25 | -16 | -451 | 46 | 69 | 173 | 101 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 92 | 85 | 103 | 49 | -277 | 106 | -113 | 104 | 83 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 51.14% | 50.73% | 45.89% | 45.11% | 44.92% | 44.82% | 41.1% | 41.71% | 42.37% | 42.66% | 42.79% | 43.46% |
| Promoters | 30.49% | 30.49% | 37.27% | 37.27% | 37.23% | 37.94% | 42.01% | 42.01% | 42.0% | 42.0% | 41.93% | 41.93% |
| FII | 16.62% | 15.8% | 14.0% | 14.25% | 14.67% | 14.63% | 14.25% | 13.58% | 11.98% | 11.59% | 11.52% | 10.71% |
| DII | 1.75% | 2.97% | 2.83% | 3.37% | 3.19% | 2.61% | 2.62% | 2.69% | 3.64% | 3.75% | 3.74% | 3.89% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Solara Active Pha Sci Ltd (this stock) | 3,347 | 70.7 | 2.33 | -0.13% |
| Unichem Laboratories Ltd | 3,511 | 29.5 | 1.26 | 3.17% |
| Advanced Enzyme Tech Ltd | 3,102 | 19.1 | 1.9 | 10.5% |
| Shukra Pharmaceuticals L | 3,639 | 82.1 | 30.56 | 28.9% |
| Ind Swift Laboratories Lt | 2,881 | 31.4 | 1.95 | 4.02% |
| Hikal Limited | 2,690 | 37.8 | 2.28 | 2.21% |
| Fredun Pharmaceuticals L | 2,548 | 48.1 | 7.59 | 15.6% |
Which Mutual Funds Hold Solara Active Pha Sci Ltd?
Frequently Asked Questions about Solara Active Pha Sci Ltd
Solara Active Pha Sci Ltd (SOLARA) closed at ₹640.6 on NSE on 19 November 2026, down 9.9 (1.52%) from the previous close.
Solara Active Pha Sci Ltd trades on the NSE (National Stock Exchange of India) under the symbol SOLARA.
Solara Active Pha Sci Ltd has a trailing twelve-month P/E (price-to-earnings) ratio of 70.7.
Solara Active Pha Sci Ltd has a dividend yield of 0.0%.
Solara Active Pha Sci Ltd's 52-week high is ₹774.0 and its 52-week low is ₹422.0.
Solara Active Pha Sci Ltd has a market capitalisation of ₹3,347 crore.
Solara Active Pha Sci Ltd has a TopFund Quality Score of 49/100 (Weak), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Solara Active Pha Sci Ltd?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.